DFDA

Nintedanib

Treatment for Interstitial Lung Disease And Pulmonary Sarcoidosis

Typical Dosage: 150 mg twice daily

Effectiveness
65%
Safety Score
40%
Clinical Trials
1
Participants
3.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
150 mg twice daily
Time to Effect
3-6 months (sustained effect)
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,500
Monitoring:$1,500
Side Effect Mgmt:$1,000
Total Annual:$10,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$280,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$18,182
Nintedanib Outcomes

for Interstitial Lung Disease And Pulmonary Sarcoidosis

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+55%
Common Side Effects
Diarrhea
+65%
Nausea
+25%
Vomiting
+10%
Liver enzyme elevation
+8%

Sources:

atsjournals.org
dntb.gov.ua
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Nintedanib in Interstitial Lung Disease And Pulmonary Sarcoidosis

RCT of Nintedanib in Fibrotic Sarcoidosis

NCT06479603RECRUITINGPHASE4
View Study
120 participants
INTERVENTIONAL
Chandigarh, India
Started: Jun 30, 2024